SCHEMBL4901692

SCHEMBL4901692

Cc1ccc2c(n1)sc1cnnnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.43
MAPT P10636 5/20 0.43
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 3/20 0.43
HPGD P15428 3/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.39
IKBKB O14920 1/20 0.38
LIMK1 P53667 1/20 0.38
RAB9A P51151 3/20 0.35
CCR1 P32246 1/20 0.35
CCR5 P51681 1/20 0.35
HTT P42858 1/20 0.34
KMT2A Q03164 2/20 0.33
MEN1 O00255 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
OPRK1 P41145 1/20 0.31
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25662805 0.76 ALDH1A1 (0.42) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL11478003 0.76 LIMK1 (0.49) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL25662800 0.74 ALDH1A1 (0.54) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL11478029 0.73 CHRM4 (0.47) ALDH1A1MAPTKDM4EHPGDSMN1; SMN2
SCHEMBL4886995 0.72 CLK1 (0.43) MAPTKDM4ENPC1HPGDSMN1; SMN2
SCHEMBL19267554 0.70 ALDH1A1 (0.53) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL11475899 0.70 MAPT (0.49) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL11477655 0.70 MAPT (0.49) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL4895941 0.70 MAPT (0.64) ALDH1A1MAPTKDM4ENPC1HPGD
SCHEMBL11479625 0.70 MAPT (0.49) ALDH1A1MAPTKDM4ENPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4239887-A ANTIALLERGENS USV PHARMACEUTICAL CORPORATION (US) 1980-12-16 US claimed
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses CYWIN CHARLES L 2008-01-10 US disclosed
US-7291733-B2 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2007-11-06 US disclosed
EP-1673374-A2 SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2006-06-28 EP disclosed
US-20050101601-A1 Substituted tricyclic heterocycles and their uses BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-05-12 US disclosed
WO-2005035537-A2 SUBSTITUTED TRICYCLIC HETEROCYCLES AND THEIR USES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-04-21 WO disclosed
US-4239887-A ANTIALLERGENS USV PHARMACEUTICAL CORPORATION (US) 1980-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101601-A1 Substituted tricyclic heterocycles and their uses LTC4S, NQO1, CBR3 ALDH1A1 270/4885MAPT 4573/4885KDM4E 3715/4885
US-20080008720-A1 Substituted Tricyclic Heterocycles and their Uses LTC4S, NQO1, CBR3 ALDH1A1 270/4885MAPT 4573/4885KDM4E 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.